Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor by Bangsgaard, N. et al.
Neutralization of IL-8 Prevents the Induction of
Dermatologic Adverse Events Associated with the
Inhibition of Epidermal Growth Factor Receptor
Nannie Bangsgaard1*, Mischa Houtkamp2, Danita H. Schuurhuis2, Paul W. H. I. Parren2, Ole Baadsgaard3,
Hans W. M. Niessen4, Lone Skov1
1Department of Dermato-allergology, Copenhagen University Hospital Gentofte, Hellerup, Denmark, 2Genmab, Utrecht, The Netherlands, 3Genmab, Copenhagen,
Denmark, 4Department of Pathology and Cardiac Surgery, VU University Medical Centre, Amsterdam, The Netherlands
Abstract
Epidermal growth factor receptor (EGFR) inhibitors are widely used in the treatment of cancer. EGFR-targeted treatment is
known to be associated with a high incidence of dermatological adverse reactions, including papulopustular rash, which
can be dose-limiting and may affect compliance to treatment. Currently, the pathways involved in EGFR inhibitor-induced
rash are poorly understood and few treatment options for this adverse event are available. Here, we developed a model for
induction of papulopustular rash in healthy human volunteers by subcutaneous injection of the anti-EGFR monoclonal
antibody zalutumumab. The injection sites and surrounding skin were evaluated by a dermatologist for the presence or
absence of papulopustular rash and skin biopsies were taken to confirm the macroscopical findings by immunohisto-
chemistry. Locally injected zalutumumab induced a papulopustular rash, characterized by acute follicular neutrophil-rich
hair follicle inflammation, and thus mimicked adverse events induced by systemic administration of EGFR inhibitors. In this
model, we tested the hypothesis that neutrophils, attracted by IL-8, play a central role in the observed rash. Indeed,
concomitant local repeat dose treatment with HuMab-10F8, a neutralizing human antibody against IL-8, reduced the rash.
Inhibition of IL-8 can therefore ameliorate dermatological adverse events induced by treatment with EGFR inhibitors.
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Introduction
Cancer therapy is increasingly shifting towards targeting specific
pathogenic pathways. Epidermal growth factor receptor (EGFR;
ErbB1) controls proliferation and maturation of epithelial cells in
skin. In many solid tumors of epithelial origin, EGFR is up-
regulated, making it an attractive target for treatment [1,2,3].
Indeed, inhibitors of EGFR, including both small molecules and
monoclonal antibodies (mAb), represent a known example of
targeted therapy, and are widely used in daily oncologic clinical
practice [4]. EGFR inhibitors are less likely than traditional
cytotoxic chemotherapeutics to cause myelosuppression, infection,
vomiting and nausea. However, several dermatological adverse
events accompany the use of EGFR inhibitors. These adverse
events affect the patient’s well being, may be dose-limiting and
influence treatment compliance. A papulopustular (also called
acneiform) skin rash is a common toxicity observed with both
EGFR-targeting mAb and tyrosine kinase inhibitors (TKI), with a
reported incidence of up to 80% in patients treated with EGFR-
targeting agents [5,6,7].
The rash induced by EGFR inhibitors typically appears within
one to three weeks of treatment and is characterized by
inflammatory follicular papules and pustules. The rash is most
commonly affecting the face; but is also seen at the upper chest
and back and infrequently at other body sites [8]. The rash
appears to be dose-related [9,10], and is reversible upon
withdrawal of treatment, but may re-appear or worsen once
treatment is resumed. Higher response rates and a significant
correlation with increased survival have been observed in patients
in whoever rash developed [11,12]. To ensure that patients can
continue to receive treatment at the optimal dose, effective
treatment strategies are required to actively manage rash and aid
compliance. As yet, there are no standardized treatments for these
skin side-effects [13,14,15]. A greater understanding of the
biological mechanisms responsible for the EGFR inhibitor-
induced rash would be highly beneficial for the development of
rational and more effective treatment management strategies.
The rash may be related to follicular occlusion due to a lack of
epithelial differentiation and epithelial inflammation resulting
from release of cytokines as direct results from EGFR inhibition.
Because the papulopustular rash is characterized by follicular
inflammation with an accumulation of neutrophils [16,17,18], we
hypothesized that the cytokine IL-8 might play a role in this
pathology. Previously, we have shown that treatment of patients
with palmoplantar pustulosis (PPP), an inflammatory disease
characterized by skin infiltration with neutrophil granulocytes,
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with a neutralizing monoclonal antibody against IL-8, led to a
marked improvement in clinical signs concomitant with a
reduction in neutrophil infiltration [19].
Here we show, in this proof-of-principle study, that inhibition of
IL-8 can ameliorate the dermatological adverse events induced
with an EGFR-inhibiting mAb. Further studies addressing the
potential of IL-8 inhibition for the prevention of serious
dermatological adverse events induced both by small molecule
as well as biologic EGFR inhibitors are warranted.
Materials and Methods
An open-label, single-center non-randomized study was per-
formed in healthy volunteers with a single dose escalation set-up.
The clinical study was performed at the Department of Dermato-
allergology, University Hospital of Copenhagen Gentofte in
accordance with the declaration of Helsinki. The study was
approved by the local ethics committee (H-KA-20060104) and
The Danish Medicines Agency (2006-003253-24). All subjects
gave written informed consent prior to enrolment.
A total of nine healthy male volunteers were included in the
study. All subjects were Caucasian men and the median age of the
group was 24 years (range 22–32 years).
Injection protocol
The first part of the study was conducted to evaluate whether
local subcutaneous (s.c.) injection of zalutumumab could induce a
papulopustular rash, similar to that reported in patients treated
systemically with EGFR inhibitors. A maximum of four subjects
were to be enrolled and attended once weekly for injection of
escalating doses of zalutumumab on the upper back. Since there
was no experience with s.c. injection of zalutumumab and the local
concentration to induce rash was not known, the study was started
with a dose-escalation of s.c. zalutumumab (see Table 1 and
Figure 1). 1 mg (in 0.2 mL) zalutumumab was injected s.c. on the
upper back. The injection site was marked for later identification.
One week later, the injection site was inspected macroscopically
and scored by a dermatologist for the presence or absence of rash,
defined by the appearance of at least one pustule. If there were no
signs of pustules, another 1 mg (in 0.2 mL) zalutumumab was
injected at the same site. At the same visit, 10 mg (0.2 mL)
zalutumumab was injected at another site, marked for later
identification. At each visit, a control injection of an identical
volume (0.2 mL) of isotonic saline was injected at a different site.
The procedure would take place once weekly with a dose-increase
of factor 10 each week, over seven weeks or until the subject had a
rash considered induced by the zalutumumab treatment. Only one
dose level was injected per injection site. Each dose level was
applied for a maximum of four weeks or until a rash developed.
Part I of the study was performed in a staggered manner (e.g.
treatment of subject 2 was only initiated one week after that of
subject 1) and this part would be considered completed when at
least one volunteer developed a rash.
The second part of the study was conducted to evaluate the
effect of the human IL-8 antibody HuMab-10F8 on zalutumu-
mab-induced papulopustular rash. Seven subjects were enrolled.
The dose-escalation procedure from the first part was repeated,
again starting at 1 mg zalutumumab per dose. Zalutumumab was
either injected alone or in combination with 1.25 mg (in 0.25 mL)
HuMab-10F8. As a negative control, isotonic saline, in the same
volume as the combined zalutumumab/HuMab-10F8 injection
(0.45 mL), was injected at a different site at each visit. After the
fourth injection of the zalutumumab/HuMab-10F8 combination
at one dose level, 1.25 mg HuMab-10F8 was injected alone once
weekly for three weeks at the combination injection site (see
Figure 1 and Table 1).
In the third and last part of the study, zalutumumab was given
in a dose-escalation procedure starting at 100 mg, or 1 mg if the
volunteer had received 100 mg earlier in the study. HuMab-10F8
was administered in a repeat dose regimen. Four subjects were
enrolled. The procedure was as described for the second part of
the study; however, an additional 1.25 mg dose of HuMab-10F8
was administered at four consecutive days after each combined
zalutumumab/HuMab-10F8 injection.
Antibodies
The therapeutic antibodies used in this study were zalutumu-
mab (2F8; HuMax-EGFr); a human IgG1, k mAb specific for
EGFR; generated as described in Bleeker et al., by immunizing
HuMAb mice with A431 cells and purified EGFR [20]. The
clinical batch was produced by Lonza Biologics (Slough, UK) from
CHO DG44 cell line DJT33. Zalutumumab binds to domain III
on the EGFR and inhibits tumor growth by a dual mechanism of
action: blockade of EGFR signaling and induction of Fc-mediated
antibody-dependent cell-mediated cytotoxicity (ADCC) [19].
Systemic administration of zalutumumab was shown to induce
rash [21]. HuMab-10F8; a human IgG1, k mAb specific for IL-8
Figure 1. Trial design. Injection schemes for the three different parts
of the study are shown. Subjects were injected with different doses of
zalutumumab at different sites, as described in Table 1. Sc – screening
of patient.
doi:10.1371/journal.pone.0039706.g001
Table 1. Dose escalation schedule for zalutumumab
injections.
Visit
Injection
site Day 0 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42
1 1 mg 1 mg 1 mg 1 mg
2 10 mg 10 mg 10 mg 10 mg
3 100 mg 100 mg 100 mg 100 mg
4 1 mg 1 mg 1 mg 1 mg
Every injection of zalutumumab was accompanied by a control injection of an
identical volume of isotonic saline at a different site. In the third part the dose
escalation started at 100 mg.
doi:10.1371/journal.pone.0039706.t001
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[19]; the clinical batch MDS001 was produced by Medarex Inc.
(New Jersey, US).
Clinical Assessment
In each study part, injection sites were evaluated once a week
and subjects were instructed to contact the investigator as soon as
pustules developed. 4-mm punch skin biopsies were taken from a
pustule when a rash was considered to be induced by
zalutumumab treatment. At the same time, control biopsies were
taken from the isotonic saline injection site and, in part two and
three of the study, the positive control site (zalutumumab alone).
The investigator assessed the degree of the rash at the marked
injection sites using the following scale from 0 to 3: 0: no rash; +1:
mild rash; +2: moderate rash; +3: severe rash. The number of
pustules at the injection site was counted and photographic
documentation obtained.
Histological and immunohistochemical assessment
Paraffin-embedded skin biopsies were cut at 4 mm thickness,
stained with HE and scored as normal or acutely inflamed.
Multiple skin sections of each biopsy were examined, to secure that
areas with inflammation deeper in the biopsies would not be
missed. HE-stained skin biopsies were scored normal when only
few diffuse macrophages or lymphocytes were detected in the
vicinity of hair follicles (sebaceous glands) and scored acutely
inflamed when, in addition to macrophages and lymphocytes,
influx of neutrophils was detected ($50 cells/skin section; semi
quantitative score). To confirm the conclusions of the HE staining
and identify the inflammatory cells, some skin biopsies were
immunostained for EGFR (mouse anti-human EGFR, clone 1F4,
cat. # 2239S, specific for the cytoplasmic domain of EGFR; does
not compete with zalutumumab for binding to EGFR; Bioke,
Leiden, The Netherlands), or with cell type-specific markers
identifying neutrophils (mouse anti-human neutrophil elastase,
clone NP57, cat. # M0752; Dako, Glostrup, Denmark) and
macrophages (mouse anti-human CD68, clone PG-M1; cat. #
M0876; Dako). The primary mouse antibodies were detected with
a peroxidase-labeled anti-mouse IgG dextran polymer (Envision-
POTM Dako, Glostrup, Denmark; Powervision-POTM, Immuno-
logic, Duiven, The Netherlands) and visualized with AEC (red
staining).
Figure 2. Histology of biopsies from saline- or zalutumumab-injected skin (part I of the study). Representative sections are shown of skin
biopsies of one subject for part I of the study (following two injections of 10 mg of zalutumumab). Sections were stained with HE to show nucleated
cells and (patho-)histological features. In the saline-injected skin (A, C), inflammatory cells were virtually absent and the hair follicle structure was
intact. Note that after zalutumumab injection (B, D), the hair follicle structure was destroyed and extensive influx of inflammatory cells (including
neutrophils) in the vicinity of the destroyed hair follicle/glandular structures can be observed (asterisks). Scale bars are 100 mm (A, B) and 20 mm (C,
D).
doi:10.1371/journal.pone.0039706.g002
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Results
Induction of papulopustular rash by local injection of
zalutumumab
To set up a human model to study EGFR inhibitor-induced
rash, healthy subjects were injected s.c. with the human anti-
EGFR antibody zalutumumab. Local injections were used to set
up a safe model in human volunteers with limited exposure to the
therapeutic antibody.
In part I of the study (Figure 1, Table 1), it was investigated
whether s.c. injection of zalutumumab could induce rash. Rash
occurred simultaneously in volunteers 1 and 2 on day 14 of the
study, which was observed as a mild rash at the 1 mg zalutumumab
injection site (i.e. following three 1 mg injections in subject 1 and
two injections in subject 2) and a milder rash at 10 mg of
zalutumumab (i.e. after two and one 10 mg injections in subjects 1
and 2, respectively). The number of pustules counted is shown in
Table 2. Histological examination of skin biopsies from zalutu-
mumab-treated areas showed acute neutrophilic inflammation
with follicular localization and signs of disruption of the hair
follicles (Table 2, Figure 2B, D), whereas in the saline-treated
normal skin, inflammatory cells were virtually absent and the hair
follicle structure was intact (Figure 2A, C).
Effect of HuMab-10F8 treatment on zalutumumab-
induced papulopustular rash
In part II of the study, it was investigated whether neutralization
of IL-8 by a neutralizing antibody, HuMab-10F8, could inhibit the
zalutumumab-induced rash. Zalutumumab and HuMab-10F8
were administered concomitantly, once weekly (Figure 1). Seven
subjects (including the two subjects from part I) were included in
this part of the study. Six of the seven subjects developed pustules
following injection of zalutumumab; one at 1 mg, one at 10 mg and
four at 100 mg (an example of the rash in shown in Figure 3, the
number of pustules counted at the site of biopsy is shown in
Table 2). Subject no. 7 was withdrawn due to an adverse reaction
(pharyngitis). No clinical or histological differences were observed
between the sites with zalutumumab/HuMab-10F8 co-injection
compared to sites injected with zalutumumab alone (Table 2). An
explanation for these results might be that we did not reach a
sufficient local concentration of the IL-8 antibody to achieve a
therapeutic effect. Therefore we extended the study with a repeat
dose regimen of HuMab-10F8. Four subjects (including the two
subjects who completed part I and II of the study and two subjects
who completed part II) were included. Zalutumumab was again
injected once a week concomitantly with HuMab-10F8 followed
by four additional injections of HuMab-10F8 (Figure 1). All four
subjects developed pustules following injection of zalutumumab,
one at 100 mg and three at 1 mg. Interestingly, an effect of
HuMab-10F8 injection on the zalutumumab-induced papulopus-
tular rash was observed in three of four subjects. Clinically, repeat
HuMab-10F8 dosing completely suppressed the induction of
pustules in two subjects and partially suppressed it in one subject
(Table 2). For the zalutumumab positive control alone, induction
of pustules was observed in these same subjects (Figure 4).
Histological examination supported the clinical findings (Figure 5,
Table 2), except in subject no. 6, who had a clinical rash, but
normal histology. An extensive influx of inflammatory cells in the
vicinity of the hair follicle and signs of folliculitis was observed in
the zalutumumab-treated skin (Figure 5 B, D, F, H, J, L). The
influx of inflammatory cells consisted predominantly of neutrophils
(Figure 5 J, L) and to a lesser extent of macrophages (Figure 5 F,
H). In the skin treated with both zalutumumab and repeat doses of
HuMab-10F8, the influx of inflammatory cells was virtually absent
and sebaceous glands and hair follicles had normal histological
features (Fig. 5 A, C, E, G, I, K).
Adverse events
Overall, five subjects experienced at least one adverse event (10
adverse events were experienced in total). Headache (two subjects),
influenza (one subject), heamatochezia (one subject) and neutro-
phil count decrease (one subject) were judged as not related to
Figure 3. Papulopustular rash was induced by local injection of
zalutumumab. The rash observed at the injection site of one subject
in part II of the study, following two injections of 100 mg of
zalutumumab each, is shown.
doi:10.1371/journal.pone.0039706.g003
Figure 4. Effect of HuMab-10F8 on zalutumumab-induced pustules. Injection sites of a patient from study part III is shown. Injection of
100 mg zalutumumab alone (E) induced pustules following two injections. Injection of zalutumumab combined with HuMab-10F8, followed by four
daily HuMab-10F8 injections (C), suppressed the induction of pustules. The saline control is also shown (N).
doi:10.1371/journal.pone.0039706.g004
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zalutumumab treatment; rash distant from the injection site (one
subject), fatigue (one subject), pharyngitis (one subject), acne (one
subject) and pruritus (one subject) were judged as related to
zalutumumab treatment. No serious adverse events were reported.
Discussion
Prevention and management of EGFR inhibitor-induced
dermatological toxicities is critical for patients on such treatments.
Histologically, the papulopustular skin rash of patients systemically
treated with EGFR inhibitors for cancer often presents with
neutrophil-rich suppurative folliculitis [16,17,18]. We set up a new
model in humans to mimic this adverse event. We here report
histological findings, similar to those observed after systemic
treatment with EGFR inhibitors, in the skin biopsies from
volunteers treated s.c. with zalutumumab. Therefore, this is a
model that is very suitable for studying the mechanism behind the
development of papulopustular rash and testing potential treat-
ment modalities. Since the model is localized, it is easy to control,
and relatively low doses of potential treatments can be studied with
minimal risk to the volunteers. We show here that neutralization of
IL-8 can ameliorate the symptoms and histological features or
EGFR inhibitor-induced papulopustular rash.
Papulopustular rash is reported in up to 80% of patients treated
with EGFR inhibitors, both small molecules and mAb [5,6,7]. The
papulopustular rash is usually mild and with minimal discomfort
[5]; however, serious discomfort and altered quality of life have
been reported, resulting in dose reductions or treatment
withdrawal [22,23] (out of an 80% overall incidence, grades 1/2
are usually reported at 60%, grades 3/4 at 5–20% [5]).
Discontinuation or interruption of cancer therapy may affect
clinical outcome. Therefore, effective treatment of these adverse
events is required. EGFR inhibitor-induced dermatological
toxicities are mainly treated symptomatically, since the mecha-
nisms behind the induction of papulopustular rash by EGFR
inhibitors are not well understood. Different agents known to be
effective in the treatment of acne such as drying agents, topical
antiseptics, topical and systemic antibiotics, topical and systemic
retinoids as well as topical and systemic steroids have been used to
symptomatically treat the rash, with varying response [5,6].
EGFR is expressed on epidermal keratinocytes, hair follicle
epithelium and sebaceous glands [24,25]. Activation of EGFR by
its ligands plays a crucial role in keratinocyte proliferation,
migration, differentiation and survival, keratinization and devel-
opment of the hair follicle [26,27,28]. EGFR inhibition in skin
induces apoptosis in normal keratinocytes, which increases five-
fold between day 4 and 12, and which correlates with median time
to rash onset in patients [29]. Furthermore, inhibition of EGFR
disrupts growth and differentiation of the hair follicle [16]. Murine
studies indicate that complete or partial abrogation of the EGFR
gene causes significantly altered and thinned epidermis and
abnormal colonic mucosa, which suggests that the down-stream
signaling cascade for EGFR is essential for normal development of
epithelial tissues [30,31]. Some anti-EGFR mAb, such as
RG83852, do not inhibit the tyrosine kinase activity of the
receptor. In a phase I study of RG83852, no skin rash was
observed at doses that produced a high level of saturation of
EGFR in vivo [32]. This observation suggests that induction of skin
rash requires effective EGFR tyrosine kinase inhibition. However,
tyrosine kinase inhibition may be necessary, but not sufficient, for
the skin rash to occur.
EGFR blockade has been demonstrated to affect chemokine
expression in keratinocytes [33]. Increased chemokine expression
after EGFR blockade has been shown to result in enhanced skin
inflammation [28]. The induced chemokines could play a role in
the inflammation with influx of neutrophils, as observed in the skin
biopsies. Several studies have aimed to identify histological and
immunohistochemical features of skin in patients treated with
EGFR inhibitors [17,18,34]. Thus, the role of tumor necrosis
Figure 5. Histology and immunohistochemistry of biopsies
from zalutumumab-injected skin treated with HuMab-10F8 or
untreated. Data shown are representative sections of skin biopsies of
one subject for part III of the study. Biopsies were taken at day 14 after
two injections with 100 mg of zalutumumab with [A, C, E, G, I, K] or
without HuMab-10F8 [B, D, F, H, J, L]. A, B: HE staining; C, D: staining for
EGFR; E–H: staining for macrophages and I–L: staining for neutrophils.
Extensive influx of inflammatory cells in the vicinity of the hair follicle
with histological signs of folliculitis was observed in zalutumumab-
injected skin (right panels), whereas in the zalutumumab-injected skin
treated with HuMab-10F8 (left panels) inflammatory cells were virtually
absent and sebaceous glands and hair follicles showed normal
histological features. Inflammatory infiltrate in the zalutumumab-
injected skin was mainly composed of neutrophils (neutrophil elastase
positive cells, J, L) and to a lesser extent of macrophages; (CD68 positive
cells F, H). Scale bars are 100 mm (A–F, I, J) and 20 mm (G, H, K, L). G, H, K
and L are magnifications of the squared areas indicated in E, F, I and J.
doi:10.1371/journal.pone.0039706.g005
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factor-a (TNF-a) and interleukin-1 (IL-1) in the development of
EGFR inhibitor-associated skin rash was shown and a possible
therapeutic role for anti-TNF agents was suggested [35]. It has
previously been described that the EGFR-specific antibody
cetuximab induced papulopustular eruptions and induced pro-
duction of IL-1 and TNF-a [36]. Cetuximab and zalutumumab
employ similar mechanisms of action. Both IL-1 and TNF-a can
induce IL-8 secretion by fibroblasts [37] and IL-1 can induce IL-8
secretion by keratinocytes [38]. IL-8 attracts and activates
neutrophils [37,39,40,41]. It was therefore hypothesized that
EGFR inhibition may (indirectly) induce the production of IL-8,
which contributes to the induction of EGFR inhibitor-induced
rash. However, it was also described that activation of EGFR
induced IL-8 production in keratinocytes in vitro [42]. This
emphasizes the difficulty of extrapolating findings obtained with
one cell type in vitro to a whole organ in vivo, in this case the skin,
which contains many different cell types that interact with each
other, and may respond distinctly. Our exploratory clinical trial
allowed us to test our hypothesis in humans in vivo.
Previously, we showed that local injection of HuMab-10F8, a
therapeutic human antibody against IL-8, induced a marked
reduction of disease activity in PPP patients [19]. In the present
study, we tested the hypothesis that local injection of this
therapeutic antibody was capable of reducing the papulopustular
rash induced by EGFR inhibition. Repeat dose treatment with
HuMab-10F8 was shown to reduce papulopustular rash induced
by local zalutumumab injections. The effect was not seen when
HuMab-10F8 was applied as a single dose once a week. Because of
the local nature of the dermatological events, histological data
were only used to illustrate that the zalutumumab-induced rash
mimicked the adverse events induced by systemic administration
of EGFR inhibitors and to examine the composition of the
infiltrate.
In addition to a role in inflammation, IL-8 was also
demonstrated to play a role in the survival of tumor cells. Blocking
IL-8 has been shown to prevent angiogenesis and reduce
tumorigenesis of human non-small cell lung cancer in SCID mice
[43]. Furthermore, the combination of antibodies targeting IL-8
with those targeting EGFR resulted in increased anti-tumor
effects, as compared with anti-EGFR alone, in a metastatic human
breast carcinoma model in SCID mice [44]. Thus, anti-IL-8 and
anti-EGFR might provide an interesting combination treatment
regimen.
In summary, we developed an innovative human model to study
dermatological adverse events induced by EGFR inhibitors. Using
this model we showed that neutralization of IL-8 by specific mAb
is capable of ameliorating these adverse events. Our study provides
a proof-of-principle for a role of IL-8-induced neutrophil
migration in the biological mechanisms involved in EGFR
inhibitor-induced rash.
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